Mantle Cell Lymphoma
Feature
High cost and demand for old cancer drug sparks crisis
Experts have voiced alarm at the scarcity and cost of fludarabine, an old drug deemed crucial to cellular therapy for leukemia.
From the Journals
Transplant provides no clear survival benefit in real-world MCL study
The findings apparently contradict the survival benefit seen in clinical trial data, authors said, but are consistent with other recent...
From the Journals
Blame MCL, not transplantation, for late effects?
In patients with mantle cell lymphoma, long-term complications appeared to be caused by the disease itself, not by intensive therapy.
From the Journals
Phase 3 trial yields better way to predict MCL outcomes
In a phase 3 trial of mantle cell lymphoma outcomes, repeated evaluations of minimal residual disease over time improved prognostic power.
From the Journals
Gloom lifting as MCL treatments evolve
A rare blood cancer remains incurable, yet new therapies have yielded improved prognoses and survival rates.
News
FDA approved acalabrutinib tablet for MCL, CLL, SLL
Acalabrutinib (Calquence) in tablet formulation approved by FDA.
From the Journals
‘Plethora’ of new MCL treatment options
New and potential treatments have emerged for relapsed/refractory mantle cell lymphoma (R/RMCL), a rare but steadily increasing form of non-...
Feature
Noted oncologist ponders death, life, care inequities
A photojournalist-turned-physician practiced in India and the United Kingdom before rising to prominence in U.S. community oncology.
News
First drug therapy approved for childhood GVHD
FDA greenlights ibrutinib for child blood cancer patients with chronic graft-versus-host disease.
From the Journals
Phase 3 data: Zanubrutinib bests standard CLL treatment
Results could spur FDA approval as frontline therapy.
Feature
Drug shortages plague hematology, but preparedness helps
The plight of desperate patients is getting attention – and some remedies.